Under terms of the deal, Richter will receive an upfront cash payment of $25 million, along with potential future development, regulatory, and commercialization milestones.
AbbVie, Gedeon Richter Ink Deal to Develop Novel Targets for Neuropsychiatric Conditions
Under terms of the deal, Richter will receive an upfront cash payment of $25 million, along with potential future development, regulatory, and commercialization milestones.
